Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT07101094 · ClinicalTrials.gov registry record

Evaluation of Treatment Satisfaction and KarXT Utilization Registry (RESKU)

A clinical trial of Schizophrenia, sponsored by Bristol-Myers Squibb.

Recruiting
Registry status
300
Enrollment target
17
Study locations

NCT07101094 is a study of Schizophrenia that is actively recruiting participants, run by Bristol-Myers Squibb. The registered enrollment target is 300 participants, above the 218-participant average among 315 other Schizophrenia trials with a reported enrollment target (38% higher). The trial reports 17 study locations across 11 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT07101094, a study of Schizophrenia, is actively recruiting participants, sponsored by Bristol-Myers Squibb.

RECRUITING
Registry status
300 participants
Enrollment target
17
Study locations

Study Summary

The purpose of this study is to understand treatment preference and satisfaction among adults with schizophrenia in the United States who are prescribed xanomeline and trospium chloride (X/T) therapy

Conditions Studied

Schizophrenia

Interventions

  • DRUG xanomeline and trospium chloride (X/T) therapy

Study Locations (17)

Maryland

  • Local Institution - 0007 - Baltimore
  • Local Institution - 0017 - Bel Air
  • Local Institution - 0004 - Catonsville

Massachusetts

  • Local Institution - 0008 - Belmont
  • Local Institution - 0002 - Boston
  • Mayflower Clinical - South Dartmouth

California

  • Local Institution - 0009 - Orange
  • Lumos Clinical Research Center - San Jose

Texas

  • Local Institution - 0012 - El Paso
  • Local Institution - 0013 - Longview

Illinois

  • Local Institution - 0003 - Evanston

Nebraska

  • Omaha Insomnia and Psychiatric Services - Omaha

New Jersey

  • Hackensack Meridian Health - Carrier Clinic - Belle Mead

New York

  • Local Institution - 0015 - New York

Trial Details

FieldValue
Enrollment Target 300 participants
Start Date 2025-09-22
Est. Completion 2029-05-14

Sponsor

Bristol-Myers Squibb

1,025 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT07101094

The ClinicalTrials.gov registry entry for NCT07101094 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 300 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 218-participant average among 315 other Schizophrenia trials with a reported enrollment target (38% higher). The listed sponsor is Bristol-Myers Squibb, which has 1,025 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Schizophrenia appearing as the primary indexed condition, and to 1 intervention - of which xanomeline and trospium chloride (X/T) therapy is the first listed.

NCT07101094 reports 17 study locations spanning 11 distinct geographic areas - top geographies include Maryland, Massachusetts, California.

Frequently Asked Questions

What is clinical trial NCT07101094 about?

NCT07101094 is a clinical study titled "Evaluation of Treatment Satisfaction and KarXT Utilization Registry (RESKU)". The purpose of this study is to understand treatment preference and satisfaction among adults with schizophrenia in the United States who are prescribed xanomeline and trospium chloride (X/T) therapy

What is the current status of trial NCT07101094?

This trial is currently recruiting. The enrollment target is 300 participants. The study started on 2025-09-22. Estimated completion is 2029-05-14.

What conditions does trial NCT07101094 study?

This clinical trial studies the following conditions: Schizophrenia.

What interventions are being tested in trial NCT07101094?

The interventions under investigation include: xanomeline and trospium chloride (X/T) therapy (DRUG).

Who is sponsoring clinical trial NCT07101094?

This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT07101094 being conducted?

This trial has 17 study locations across California, Illinois, Maryland, Massachusetts, Nebraska. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Schizophrenia

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Schizophrenia

All registered trials for this condition

California

All trials with a study site in California

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.